LY3298176 · Dual GIP/GLP-1 Receptor Agonist · Lyophilized Powder
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Widely studied for its effects on insulin secretion dynamics, glucose metabolism, and metabolic regulatory networks.
For Research Use Only · Not for Human Consumption
Tirzepatide is a novel dual agonist at both the GIP and GLP-1 receptors, making it a unique research tool for studying the coordinated effects of incretin hormones on metabolic regulation. It is supplied as a lyophilized powder at ≥99% purity confirmed by HPLC. Each batch is independently tested and arrives with a full COA.
Tirzepatide has generated significant interest in metabolic research due to its dual mechanism of action. Unlike single GLP-1 agonists, its simultaneous engagement of GIP receptors provides researchers with a compound that can probe the synergistic effects of two major incretin pathways.
For laboratory research use only. Consult relevant literature before designing experimental protocols.
| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual | White lyophilized powder | Conforms | PASS |
| HPLC Purity | HPLC-UV | ≥99.0% | 99.4% | PASS |
| MS Identity | LC-MS/MS | MW 4813.5 ±1% | Conforms | PASS |
| Heavy Metals | ICP-MS | <10 ppm total | <2 ppm | PASS |
| Endotoxin | LAL | <5 EU/mg | <1 EU/mg | PASS |
| Sterility | USP <71> | No growth | No growth | PASS |
| Water Content | Karl Fischer | <5% | 2.9% | PASS |
Testing by accredited U.S. third-party laboratory. Full COA PDF available upon request.